LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

What Was Tested

The paper reports a study of Retatrutide and Glucagon, published as a randomized controlled trial.

LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors that is currently in development for the treatment of type 2 diabetes and for the treatment of obesity and associated comorbidities.

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Retatrutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Retatrutide could be set against what happens without it.

This trial is registered at ClinicalTrials.gov, NCT04143802.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucose and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide and Glucagon.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Lancet (London, England)), a journal based in England.

More context: the Retatrutide compound page and the Glucagon compound page, all human trials.